FEN1 and cancer: Our studies aiming to expand the potential clinical reach of FEN1 inhibitors beyond the HRD setting, identified EWS cells and more generally, SLFN11 expressing cancer cells, as potentially sensitive populations (Fig. 6E–G), which is consistent with the role of Schlafen-11 in response to RS-inducing DDRi/DDAs [84–86].